Clinical trials: Allogeneic Stem-Cell Transplant
Graft-Versus-Host Disease(GVHD)
Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.
Study Title: A Study on the Effects and Mechanisms of Omega-3 Polyunsaturated Fatty Acids on Acute Graft-Versus-Host Disease (aGVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation Study Type: Open-label, randomized…
- Trial name
- NCT07162688
- Testing
- Omega-3 Lipid Emulsion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Medical University
Renal Cell Cancer
Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objectives: 1. To compare the overall survival of metastatic renal cell carcinoma (RCC) patients undergoing HLA-matched related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) using…
- Trial name
- NCT00429026
- Testing
- Fludarabine, Melphalan, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
The VERDI study is an investigator-initiated, multicenter, multicohort, phase II trial with combination of venetoclax + azacitidine for patients treated for AML under according to an intensive chemotherapy protocol (CETLAM-20)…
- Trial name
- VERDI (NCT06668558)
- Testing
- Azacitidine (AZA), Venetoclax
- Where
- 14 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Graft Versus Host Disease
Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation
Graft versus host disease (GVHD) is one of the major causes of death in patients undergoing allogeneic hematopoietic cell transplantation.
- Trial name
- NCT01385124
- Testing
- Oral Cannabidiol
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
The purpose of this trial is to evaluate a CMV vaccine given to related donor/recipient pairs (donors prior to peripheral blood stem cell donation and CMV-seropositive recipients just before and after transplantation) and…
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma
- Trial name
- NCT00285259
- Testing
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Astellas Pharma Inc
Moxibustion, Hematopoietic Stem Cell Transplantation
Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT
This study was a prospective, multicenter, single-arm clinical study planned to enroll 60 patients who developed hemorrhagic cystitis after sexually allogeneic hematopoietic stem cell transplantation Patients with hemorrhagic…
- Conditions
- Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Treatment
- Trial name
- NCT06241274
- Testing
- Moxibustion, Symptomatic supportive treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Graft Vs Host Disease, Graft-versus-host-disease
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
This Phase II open label study will evaluate the safety and efficacy of repeat doses of RGI-2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following…
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Acute-graft-versus-host Disease, Prevention of aGVHD
- Trial name
- NCT04014790
- Testing
- RGI-2001, Standard of Care
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Regimmune Corporation
Stem Cell Transplant, Allogeneic
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant.
- Trial name
- EXCESS (NCT01189786)
- Testing
- CliniMACS CD34 Reagent system
- Where
- 2 sites in United States
- Volunteers
- 241 people
- Sponsor
- Baylor College of Medicine
Leukemia, HSCT
Comparison of Intralipid With SMOF Lipid Following HSCT
The goal of this clinical trial is to have a successful engraftment in after bone transplantation. Acute leukemia patient of both sexes aged 2 to 18 years, who are transplant candidates, participate in this study.
- Trial name
- NCT06625372
- Testing
- SMOF lipid, INTRALIPIDS
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
This project is a key clinical research project approved by the Clinical Research Center of the First Affiliated Hospital of Xi 'an Jiaotong University.Tyrosine kinase inhibitors (TKI) combined with chemotherapy and subsequent…
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult
- Trial name
- NCT05024357
- Testing
- Dasatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Graft-versus-Host Disease (GVHD), Hematologic Malignancies
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing…
- Conditions
- Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation
- Trial name
- GVHD-PTCy (NCT06926595)
- Testing
- Cyclophosphamide (primary intervention for GVHD prophylaxis)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Milton S. Hershey Medical Center
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
This is a prospective, open label, single arm, multi-centre phase II trial aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as prophylactic consolidation in patients with IDH2-mutated MDS, CMML…
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT04522895
- Testing
- Enasidenib
- Where
- 11 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Myeloma
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
The purpose of the study is to determine the safety of MLN9708 as maintenance therapy following allogeneic stem cell transplant in patients with multiple myeloma.
- Trial name
- NCT02168101
- Testing
- MLN9708
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- SCRI Development Innovations, LLC
CLL
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)
17p-/p53-mutated chronic lymphocytic leukemia (CLL) is an orphan disease, accounting for approximately 5% of newly diagnosed CLL. This subgroup of patients has a very poor outcome after chemoimmunotherapy.
- Trial name
- 17p-CLL (NCT01675102)
- Where
- 10 sites in Denmark, Finland and 5 more
- Volunteers
- 41 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Metachromatic Leukodystrophy
Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation
There is currently no effective treatment for late infantile MLD once clinical symptoms are evident. METAZYM is a recombinant human arylsulfatase A developed for an intravenous ERT for the treatment of late infantile MLD.
- Trial name
- Azylis (NCT01303146)
- Testing
- rhARSA
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hodgkins Lymphoma
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP…
- Trial name
- NCT01636388
- Testing
- allogeneic donor derived LMP specific cytotoxic T-lymphocyte
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Kidney Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00027573
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
aGVHD Prophylaxis
Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis
Gecacitinib hydrochloride is a novel JAK/ACVR1 inhibitor approved for intermediate- and high-risk myelofibrosis (MF). Clinical and real-world data demonstrate significant efficacy in spleen reduction, symptom relief, and anemia…
- Trial name
- Gecacitinib (NCT07440654)
- Testing
- Gecacitinib
- Volunteers
- 40 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Pulmonary Complications
Pulmonary Complications of Allografts
This is a prognostic study of the late lung complications arising at the patient's having received an allograft of hematopoetic stem cells.
- Trial name
- ALLOPULM (NCT01219972)
- Where
- France
- Volunteers
- 245 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.